BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?

BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.

Zacks Equity Research

4 min read

BrightSpring Health Services, Inc. BTSG stock has surged nearly 59% year to date, significantly outperforming the Medical Services industry's 1.7% gain and the S&P 500's 12.2% rise. The rally reflects investor optimism around the company's strong execution, accelerating earnings growth and expanding home-based healthcare platform.

BrightSpring reinforced this momentum with strong second-quarter 2026 results. Revenues rose 23% year over year to $3.9 billion, while adjusted EBITDA jumped 44% with margin expansion. The company also raised its 2026 EBITDA outlook, reduced leverage to 2.15x and continued expanding its Specialty Pharmacy and Provider Services businesses, positioning it for sustained long-term growth.

What Is Fueling BTSG's Growth?

Specialty Pharmacy Is Driving Growth: BrightSpring's Specialty and Infusion business remains its biggest growth engine. In the second quarter, the segment delivered 30% revenue growth and 31% script growth, supported by strong demand for branded oncology therapies and expanding partnerships in rare, orphan and other complex diseases. The company ended the quarter with 155 Limited Distribution Drugs (LDDs) and launched 12 new LDDs through the first half of 2026, strengthening its competitive position.

Provider Services Continue to Gain Momentum: BrightSpring's Provider Services business is benefiting from rising demand for home-based care. Segment revenues climbed 30% year over year in the second quarter, while Home Health revenues surged 51% on strong patient volumes, de novo expansion and contributions from acquired Amedisys and LHC branches. Management also increased expected 2026 EBITDA contribution from these acquired assets to approximately $35 million, highlighting successful integration efforts.

AI and Automation Are Expanding Profitability: BrightSpring is using AI and automation to improve efficiency across hiring, onboarding, documentation, medication reviews and patient care planning. These initiatives helped lift adjusted EBITDA 44% year over year in the second quarter, while EBITDA margin expanded 80 basis points to 5.3%. Management expects roughly $600 million in operating cash flow this year as these productivity initiatives continue to support long-term profitability.

A Strong Balance Sheet Supports Future Expansion: BrightSpring has strengthened its financial position, giving it greater flexibility to pursue growth opportunities. The company reduced leverage to 2.15x, refinanced debt at a lower spread and secured credit-rating upgrades from both Moody's and S&P. Management also highlighted a robust pipeline of tuck-in acquisitions and geographic expansion opportunities, positioning the company to sustain growth beyond 2026.

Image Source: Zacks Investment Research

BTSG’s Estimates

The Zacks Consensus Estimate for BTSG’s 2026 and 2027 earnings per share (EPS) implies year-over-year growth of 78% and 24.5%, respectively, to $1.78 and $2.21. In the past 60 days, the consensus mark for the company's 2026 EPS has improved 11 cents.

Revenues for 2026 are projected to increase 18.1% to $15.24 billion and another 12.9% to $17.22 billion in 2027.

Risks and Challenges

BrightSpring's strong growth trajectory also comes with execution risks. The company is expanding its Specialty Pharmacy, Infusion and Provider Services businesses while integrating acquired assets and pursuing additional tuck-in acquisitions. Sustaining growth will depend on maintaining strong execution across these businesses and successfully scaling new markets.

The company also continues to face external headwinds. IRA-related pricing changes are expected to weigh on Home and Community Pharmacy revenues, while reimbursement changes and competitive pressures remain ongoing risks. Although management expects operational improvements and AI-driven efficiencies to help offset these challenges, execution will remain critical.

BrightSpring Health Services, Inc. Price

BrightSpring Health Services, Inc. price | BrightSpring Health Services, Inc. Quote

Conclusion

BrightSpring's strong 2026 performance reflects a business that is growing rapidly while becoming more profitable. Robust revenue growth, expanding Specialty Pharmacy volumes, accelerating home-based care services and AI-driven operational efficiencies are strengthening its long-term growth profile. A healthier balance sheet, lower leverage and a disciplined acquisition strategy further support its expansion plans.

While reimbursement headwinds, IRA-related revenue pressure and continued execution across multiple growth initiatives remain important watch points, BrightSpring's raised 2026 outlook and strong operating momentum reinforce its long-term growth story. Backed by a Zacks Rank #1 (Strong Buy), the stock appears well positioned for investors seeking exposure to the expanding home-based healthcare market.

Other Stocks to Consider

Some other top-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO.

Globus Medical, currently sporting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report